{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:31:38Z","timestamp":1760189498666},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00277-016-2705-z","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T01:54:25Z","timestamp":1465869265000},"page":"1287-1293","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience"],"prefix":"10.1007","volume":"95","author":[{"given":"J.","family":"Bourcier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gastinne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Leux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Blin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Dubruille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Voldoire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Juge-Morineau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Jardel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"key":"2705_CR1","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S, Davies AJ, Matthews J et al (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 25:2426\u20132433. doi: 10.1200\/JCO.2006.09.3260","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2705_CR2","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M et al (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:5165\u20135169. doi: 10.1200\/JCO.2008.16.0283","journal-title":"J Clin Oncol"},{"key":"2705_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","volume":"157","author":"A Conconi","year":"2012","unstructured":"Conconi A, Ponzio C, Lobetti-Bodoni C et al (2012) Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 157:188\u2013196. doi: 10.1111\/j.1365-2141.2012.09054.x","journal-title":"Br J Haematol"},{"key":"2705_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M et al (2015) Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126:851\u2013857. doi: 10.1182\/blood-2015-01-621375","journal-title":"Blood"},{"key":"2705_CR5","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732. doi: 10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"key":"2705_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417\u20131423. doi: 10.1182\/blood-2004-08-3175","journal-title":"Blood"},{"key":"2705_CR7","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol Off J Am Soc Clin Oncol 25:1986\u20131992. doi: 10.1200\/JCO.2006.06.4618","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2705_CR8","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112:4824\u20134831. doi: 10.1182\/blood-2008-04-153189","journal-title":"Blood"},{"key":"2705_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42\u201351. doi: 10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet"},{"key":"2705_CR10","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21:3918\u20133927. doi: 10.1200\/JCO.2003.10.023","journal-title":"J Clin Oncol"},{"key":"2705_CR11","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","volume":"26","author":"C Sebban","year":"2008","unstructured":"Sebban C, Brice P, Delarue R et al (2008) Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26:3614\u20133620. doi: 10.1200\/JCO.2007.15.5358","journal-title":"J Clin Oncol"},{"key":"2705_CR12","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004\u20134013. doi: 10.1182\/blood-2007-10-116749","journal-title":"Blood"},{"key":"2705_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","volume":"96","author":"S Gouill Le","year":"2011","unstructured":"Le Gouill S, De Guibert S, Planche L et al (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica 96:1128\u20131135. doi: 10.3324\/haematol.2010.030320","journal-title":"Haematologica"},{"key":"2705_CR14","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MHJ Oers van","year":"2006","unstructured":"van Oers MHJ, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295\u20133301. doi: 10.1182\/blood-2006-05-021113","journal-title":"Blood"},{"key":"2705_CR15","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MHJ Oers van","year":"2010","unstructured":"van Oers MHJ, Van Glabbeke M, Giurgea L et al (2010) Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853\u20132858. doi: 10.1200\/JCO.2009.26.5827","journal-title":"J Clin Oncol"},{"key":"2705_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. doi: 10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"2705_CR17","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","volume":"15","author":"W Brugger","year":"2004","unstructured":"Brugger W, Hirsch J, Gr\u00fcnebach F et al (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15:1691\u20131698. doi: 10.1093\/annonc\/mdh425","journal-title":"Ann Oncol"},{"key":"2705_CR18","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1093\/annonc\/mds202","volume":"23","author":"F Morschhauser","year":"2012","unstructured":"Morschhauser F, Recher C, Milpied N et al (2012) A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol 23:2687\u20132695. doi: 10.1093\/annonc\/mds202","journal-title":"Ann Oncol"},{"key":"2705_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/bmt.2008.382","volume":"43","author":"LK Hicks","year":"2009","unstructured":"Hicks LK, Woods A, Buckstein R et al (2009) Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 43:701\u2013708. doi: 10.1038\/bmt.2008.382","journal-title":"Bone Marrow Transplant"},{"key":"2705_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1862","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C et al (2013) Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol Off J Am Soc Clin Oncol. doi: 10.1200\/JCO.2012.47.1862","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2705-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2705-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2705-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T01:51:45Z","timestamp":1467251505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2705-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["2705"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2705-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]}}}